01/22/2026 | Press release | Distributed by Public on 01/22/2026 16:03
|
Delaware
|
11-3516358
|
|
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification Number.)
|
|
8 Davis Drive
Durham, NC
|
27713
|
|
|
(Address of principal executive offices)
|
(Zip code)
|
|
Ocuphire Pharma, Inc. 2020 Equity Incentive Plan
|
|
(Full title of the plan)
|
|
Dr. George Magrath
Chief Executive Officer
Opus Genetics, Inc.
8 Davis Drive
Durham, NC 27713
(984) 884-6030
|
|
(Name, address, and telephone number, including area code, of agent for service)
|
|
Large accelerated filer ☐
|
Accelerated filer ☐
|
|
Non-accelerated filer ☒
|
Smaller reporting company ☒
|
|
Emerging growth company ☐
|
| Item 3. |
Incorporation of Documents By Reference.
|
| (a) |
the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 31, 2025 (the "2024 Annual Report");
|
| (b) |
the Registrant's Quarterly Reports on Form 10-Q, filed with the Commission on May 15, 2025, August 13, 2025 and November 12, 2025;
|
| (c) |
the Registrant's Current Reports on Form 8-K, filed with the Commission on January 7, 2025, January 14, 2025, January 23, 2025, January 24, 2025, March 4, 2025, March 20, 2025, March 24, 2025, April 4, 2025, May 1, 2025, June 20, 2025, June 25, 2025, June 26, 2025, July 23, 2025, August 25, 2025, September 2, 2025, September 30, 2025, November 6, 2025, November 6, 2025, and December 19, 2025; and
|
| (d) |
the description of the Registrant's Common Stock contained in the Registrant's Form 8-A (File No. 001-34079), as filed with the Commission pursuant to Sections 12(b) and 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), on June 7, 2019, including any amendments or reports filed for the purpose of updating such description, including Exhibit 4.12 to the 2024 Annual Report.
|
| Item 8.1 |
Exhibits.
|
|
Exhibit
Number
|
Description
|
|
Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant's Quarterly Report on Form 10-Q, filed with the Commission on August 13, 2024).
|
|
|
Certificate of Amendment to the Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K, filed with the Commission on October 22, 2024).
|
|
|
Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K, filed with the Commission on March 20, 2025).
|
|
|
Ocuphire Pharma, Inc. 2020 Equity Incentive Plan (incorporated by reference to Annex D to the Registrant's Registration Statement on Form S-4, filed with the Commission on July 6, 2020).
|
|
|
5.1*
|
Opinion of Sidley Austin LLP.
|
|
23.1*
|
Consent of Ernst & Young LLP.
|
|
23.2*
|
Consent of Sidley Austin LLP (included in Exhibit 5.1).
|
|
24.1*
|
Power of Attorney (included after the signature of the Registrant contained on Signature Page of this Registration Statement).
|
|
107*
|
Filing Fee Table.
|
|
OPUS GENETICS, INC.
|
||
|
By:
|
/s/ Dr. George Magrath
|
|
|
Name:
|
Dr. George Magrath
|
|
|
Title:
|
Chief Executive Officer
|
|
|
SIGNATURE
|
TITLE
|
DATE
|
||
|
/s/ Dr. George Magrath
|
||||
|
Dr. George Magrath
|
Chief Executive Officer & Director
(Principal Executive Officer)
|
January 22, 2026
|
||
|
/s/ Robert Gagnon
|
||||
|
Robert Gagnon
|
Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)
|
January 22, 2026
|
||
|
/s/ Cam Gallagher
|
||||
|
Cam Gallagher
|
Chair of the Board
|
January 22, 2026
|
||
|
/s/ Sean Ainsworth
|
||||
|
Sean Ainsworth
|
Director
|
January 22, 2026
|
||
|
/s/ Dr. Jean Bennett
|
||||
|
Dr. Jean Bennett
|
Director
|
January 22, 2026
|
||
|
/s/ Susan K. Benton
|
||||
|
Susan K. Benton
|
Director
|
January 22, 2026
|
||
|
/s/ Dr. Adrienne Graves
|
||||
|
Dr. Adrienne Graves
|
Director
|
January 22, 2026
|
||
|
/s/ Dr. James S. Manuso
|
||||
|
Dr. James S. Manuso
|
Director
|
January 22, 2026
|
||
|
/s/ Richard J. Rodgers
|
||||
|
Richard J. Rodgers
|
Director
|
January 22, 2026
|
||
|
/s/ Dr. Benjamin R. Yerxa
|
||||
|
Dr. Benjamin R. Yerxa
|
President and Director
|
January 22, 2026
|